Organogenesis (NASDAQ:ORGO) Stock Rating Lowered by Wall Street Zen

Organogenesis (NASDAQ:ORGO) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday.

A number of other equities analysts also recently issued reports on ORGO. BTIG Research downgraded shares of Organogenesis from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. UBS Group set a $3.00 price target on shares of Organogenesis in a report on Thursday, May 28th. Truist Financial reduced their price objective on shares of Organogenesis from $3.00 to $2.00 and set a “hold” rating for the company in a research report on Friday. Finally, Weiss Ratings cut shares of Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $4.33.

Organogenesis Price Performance

Shares of NASDAQ ORGO opened at $1.86 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.52 and a quick ratio of 3.00. The company has a 50-day moving average price of $2.42 and a 200-day moving average price of $2.75. The stock has a market capitalization of $239.34 million, a P/E ratio of -2.16 and a beta of 1.34. Organogenesis has a 1 year low of $1.54 and a 1 year high of $7.08.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.36). The business had revenue of $43.76 million during the quarter, compared to the consensus estimate of $54.27 million. Organogenesis had a negative net margin of 19.94% and a negative return on equity of 23.89%.

Institutional Trading of Organogenesis

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quarry LP bought a new position in Organogenesis in the 3rd quarter worth about $25,000. Flagship Harbor Advisors LLC purchased a new position in Organogenesis during the 4th quarter valued at about $34,000. Pallas Capital Advisors LLC bought a new stake in shares of Organogenesis during the second quarter valued at about $37,000. Federated Hermes Inc. increased its position in shares of Organogenesis by 52.8% during the fourth quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after buying an additional 2,953 shares during the period. Finally, Walleye Capital LLC purchased a new stake in shares of Organogenesis in the second quarter worth about $45,000. 49.57% of the stock is currently owned by institutional investors.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.